How Senolytic Compounds Fight Both Aging and Alzheimer's Disease
Summary by AMPLYFI
4 Articles
4 Articles
All
Left
3
Center
Right

+2 Reposted by 2 other sources
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation
·Hamilton, Canada
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left3Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage